New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

270.99 3.89 +1.46%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Johnson & Johnson (JNJ) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Johnson & Johnson (JNJ) trades at a EV/FCF of 31.5×. Over the past ten years it has ranged from 12.0× (August 2015) to 35.0× (June 2026); the current reading is higher than 99% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 25.3× 46.80%
FY2024 17.3× (21.30%)
FY2023 21.9× (17.66%)
FY2022 26.6× 21.57%
FY2021 21.9× 6.50%
FY2020 20.6× 21.40%
FY2019 17.0× 4.08%
FY2018 16.3× (17.50%)
FY2017 19.7× 11.51%
FY2016 17.7× 33.69%

Quarterly newest first

Period EV/FCF Change
Sep 2026 31.3× 13.17%
Jun 2026 27.6× (16.52%)
Mar 2026 33.1× 30.60%
Dec 2025 25.3× 8.77%
43 more quarters

Against its own ten years

Low 12.0× High 35.0×
Ten-year median 19.0×
Current reading's percentile 98

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on JNJ